Skip to main content
. Author manuscript; available in PMC: 2022 Feb 14.
Published in final edited form as: Oncogene. 2021 Feb 9;40(10):1806–1820. doi: 10.1038/s41388-021-01667-y

Figure 7. ACSL1 promotes growth of prostate xenograft tumors in vivo.

Figure 7.

(A-I) 22Rv1, PC-3 and DU145 cells transduced with control (shCon) or shRNA-ACSL1 were implanted in SCID mice subcutaneously. Each animal carried a tumor expressing control or shRNA-ACSL1 in each flanking side (see Supplemental Figure S8). After 8 weeks, tumors were harvested and representative images are shown for shCon (top) and shACSL1 (bottom) in A, D, G. Volume and weight of 22Rv1 (B-C), PC-3 (E-F) and DU145 (H-I) xenograft tumors were determined. Data are represented as mean ± SD (n=6). Student’s t test; *: p<0.05; **: p<0.01. (J-M) Expression levels of Ki67 (J and L) and CD34 (K and M) were determined in xenograft tumors expressing shRNA-control (shCon) or shRNA-ACSL1 by IHC staining (scale bars: 100 μm), and were quantified based on IHC staining.